-DOCSTART- -X- O
The -X- _ O
development -X- _ O
of -X- _ O
a -X- _ O
safe -X- _ O
and -X- _ O
effective -X- _ O
tetravalent -X- _ O
dengue -X- _ O
vaccine -X- _ O
that -X- _ O
elicits -X- _ O
protection -X- _ O
against -X- _ O
all -X- _ B-Patient
dengue -X- _ I-Patient
virus -X- _ I-Patient
( -X- _ I-Patient
DENV -X- _ I-Patient
) -X- _ I-Patient
serotypes -X- _ I-Patient
is -X- _ O
urgently -X- _ O
needed. -X- _ O
The -X- _ O
consensus -X- _ O
sequence -X- _ O
of -X- _ O
the -X- _ O
ectodomain -X- _ O
of -X- _ O
envelope -X- _ O
( -X- _ O
E -X- _ O
) -X- _ O
protein -X- _ O
of -X- _ O
DENV -X- _ O
( -X- _ O
cE80 -X- _ O
) -X- _ O
has -X- _ O
been -X- _ O
examined -X- _ O
as -X- _ O
an -X- _ O
immunogen -X- _ O
previously. -X- _ O
In -X- _ O
the -X- _ O
current -X- _ O
study -X- _ O
, -X- _ O
a -X- _ O
cE80 -X- _ B-Intervention
DNA -X- _ I-Intervention
( -X- _ I-Intervention
D -X- _ I-Intervention
) -X- _ I-Intervention
vaccine -X- _ I-Intervention
was -X- _ O
constructed -X- _ O
and -X- _ O
evaluated -X- _ O
in -X- _ O
conjunction -X- _ O
with -X- _ O
the -X- _ O
cE80 -X- _ B-Intervention
protein -X- _ I-Intervention
( -X- _ I-Intervention
P -X- _ I-Intervention
) -X- _ I-Intervention
vaccine -X- _ I-Intervention
to -X- _ O
examine -X- _ O
whether -X- _ O
both -X- _ O
vaccines -X- _ O
used -X- _ O
together -X- _ O
can -X- _ O
further -X- _ O
improve -X- _ O
the -X- _ O
immune -X- _ O
responses. -X- _ O
The -X- _ O
cE80 -X- _ O
DNA -X- _ O
vaccine -X- _ O
was -X- _ O
administrated -X- _ O
using -X- _ O
either -X- _ O
a -X- _ O
homologous -X- _ B-Comparison
( -X- _ I-Comparison
DNA -X- _ I-Comparison
alone -X- _ I-Comparison
, -X- _ I-Comparison
DDD -X- _ I-Comparison
) -X- _ I-Comparison
or -X- _ I-Comparison
heterologous -X- _ I-Comparison
( -X- _ I-Comparison
DNA -X- _ I-Comparison
prime-protein -X- _ I-Comparison
boost -X- _ I-Comparison
: -X- _ I-Comparison
DDP -X- _ I-Comparison
or -X- _ I-Comparison
DPP -X- _ I-Comparison
) -X- _ I-Comparison
regimen -X- _ I-Comparison
, -X- _ O
and -X- _ O
evaluated -X- _ O
for -X- _ O
immunogenicity -X- _ O
and -X- _ O
protective -X- _ O
efficacy -X- _ O
in -X- _ O
mice. -X- _ B-Patient
Among -X- _ O
the -X- _ O
three -X- _ O
DNA-based -X- _ O
immunization -X- _ O
regimens -X- _ O
tested -X- _ O
, -X- _ O
DDP -X- _ B-Outcome
immunization -X- _ I-Outcome
is -X- _ I-Outcome
the -X- _ I-Outcome
optimal -X- _ I-Outcome
immunization -X- _ I-Outcome
regimen -X- _ I-Outcome
that -X- _ I-Outcome
elicited -X- _ I-Outcome
the -X- _ I-Outcome
greatest -X- _ I-Outcome
systemic -X- _ I-Outcome
immune -X- _ I-Outcome
response -X- _ I-Outcome
and -X- _ I-Outcome
conferred -X- _ I-Outcome
protection -X- _ I-Outcome
against -X- _ I-Outcome
all -X- _ I-Outcome
four -X- _ I-Outcome
DENV -X- _ I-Outcome
serotypes. -X- _ I-Outcome
This -X- _ O
work -X- _ O
provides -X- _ O
innovative -X- _ O
ideas -X- _ O
for -X- _ O
the -X- _ O
development -X- _ O
of -X- _ O
consensus -X- _ O
E-based -X- _ O
dengue -X- _ O
vaccines -X- _ O
and -X- _ O
the -X- _ O
testing -X- _ O
of -X- _ O
optimal -X- _ O
immunization -X- _ O
regimens -X- _ O
. -X- _ O

